Up Close With Russian Investor Rusnano: A Q&A With Anatoly Chubais
Executive Summary
In 2007, the Russian government committed $10 billion to invest in nanotechnology. About half of that has been invested, with little to show for it so far. After a recent shake-up, Rusnano is looking to prove itself and attract the private investors that could allow it eventually to privatize.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q3 2013
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
Financings Of The Fortnight: Rusnano Dodging Controversy, Transforming Into Private Equity Fund
The Russian sovereign fund is a major investor in several U.S. life sciences start-ups. Plus news on recent financings by SAGE Therapeutics, Macrogenics, G1 Therapeutics and TD1 Innovations.
Regado Snags $51M From Venture Funding Led By Rusnano
New Jersey biotech Regado Biosciences raised $51 million in a Series E offering led by Russian investment group Rusnano. The money will be used to initiate a Phase III trial of its anticoagulant REG1.